# Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

> **NCT04397601** · — · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 220 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Folfiri/Bevacizumab
- **DRUG:** Folfiri/Aflibercept

## Key facts

- **NCT ID:** NCT04397601
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-11
- **Primary completion:** 2023-05-11
- **Final completion:** 2024-05-11
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397601, "Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04397601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*